| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_588ea75dd0165bad6c2dfc6bfd914c2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afb8acdeb99a4ab18faf321caaec610b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abc5f71fca1667dd4bea9e9fcd8e70db |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate |
2011-11-28^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-08-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01d6f33abde8dd8968b1e64b4a3a8dc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_756ab260f482c01e369b63f22270ff4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46475603b5902b0983783012bed49d33 |
| publicationDate |
2016-08-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9428491-B2 |
| titleOfInvention |
Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof |
| abstract |
The present invention relates to novel antiviral active 5-{4-[1H-imidazol-5-ylaryl(or hetaryl)]-buta-1,3-diynyl}-1H-imidazoles of the general formula 1 and pharmaceutically acceptable salt thereof, pharmaceutical composition, antiviral medicament, therapeutic kit for prophylaxis and treatment of hepatisis C virus diseases, and method for prophylaxis and treatment of hepatisis C. n nwherein:n nR 1 and R 2 —represent optionally identical radicals selected from 2.1 and 2.2, where an asterisk (*) denotes the position of attachment to the imidazole fragment, (S) and (R) are types of chiral centers;n n nR 3 is isopropyl or phenyl radicals;n nAr an aromatic or heteroaromatic diradical. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018160088-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018160090-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020246910-A1 |
| priorityDate |
2010-11-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |